Is your mAb optimized for
SubQ yet?

Cutting edge, viscosity-reduction technology for
monoclonal antibodies

Our patented platform technology uses GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing and enhanced market acceptance.

Schedule a call with us to know more

HILOPRO Technology

®

Upgrade your mAb from IV to SubQ.

Re-imagine your biologic API delivered subcutaneously in a single dose up to 450mg in a 1.5mL syringe.

Case Studies

Information Deck

Proof of concept for your mAb in
8 Weeks !

Qprotyn Contact

Is your mAb optimized for SubQ yet?

Cutting edge, viscosity-reduction technology for monoclonal antibodies

HILOPRO Technology

®

Proof of concept for your mAb in 8 Weeks !

Is your mAb optimized for
SubQ yet?

Cutting edge, viscosity-reduction technology for
monoclonal antibodies

Proof of concept for your mAb in
8 Weeks !